Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s71, 2022. DOI: 10.25251/skin.6.supp.71. Disponível em: https://skin.dermsquared.com/skin/article/view/1827. Acesso em: 8 jun. 2025.